Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9364473B2 · kind B2 · utility
11Cited by
26References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 3, 2015 |
| Grant date | Jun 14, 2016 |
| Priority date | — |
| Expiry date | Sep 3, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.